8-K: Incannex Healthcare Achieves Key Milestone for IHL-42X OSA Trial, Top-Line Results Expected July 2025

Incannex Healthcare Inc. has achieved database lock for its RePOSA Phase 2 clinical trial of IHL-42X for obstructive sleep apnoea, on schedule, with top-line results anticipated in July 2025.

Summary

• Incannex Healthcare Inc. announced the achievement of database lock for its RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea (OSA).
• This significant milestone was achieved on schedule as of June 16, 2025, marking the completion of clinical data collection and enabling the commencement of final statistical analysis.
• The company is on track to deliver top-line results from the U.S. Phase 2 portion of the trial in July 2025.
• IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide, designed to treat moderate to severe OSA in patients who are unable or unwilling to use continuous positive airway pressure (CPAP).
• The drug uniquely targets two physiological pathways associated with OSA: intermittent hypoxia (IH) and hypercapnia.
• A prior Australian Phase 2 clinical trial demonstrated that IHL-42X reduced the Apnea-Hypopnea Index (AHI) by an average of 51% relative to baseline at the lowest dose.
• Obstructive Sleep Apnoea affects over 900 million people globally and approximately 30 million people in the United States, representing a vast and underserved market with no currently approved oral pharmacological treatment.

Sentiment

Score: 8

Explanation: The announcement is highly positive, confirming the on-schedule progression of a key clinical trial for a drug targeting a large, underserved market with no current oral pharmacological treatment. The achievement of database lock is a significant de-risking event, and the anticipation of top-line results next month adds to the positive sentiment.

Positives

• Achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X on schedule as of June 16, 2025, demonstrating strong clinical capabilities and execution.
• Completion of clinical data collection enables final statistical analysis to begin, moving the program closer to key data readouts.
• The company is on track to deliver top-line results in July 2025, reinforcing confidence in the program's momentum.
• IHL-42X is positioned as a potential first-in-class, market-leading therapeutic solution for Obstructive Sleep Apnoea (OSA), addressing a significant unmet medical need.
• OSA affects over 900 million people globally, with approximately 30 million in the U.S., representing a vast and underserved patient population with no approved oral pharmacological treatment.
• Prior Australian Phase 2 clinical trial showed IHL-42X reduced the Apnea-Hypopnea Index (AHI) by an average of 51% relative to baseline at the lowest dose, indicating promising efficacy.
• IHL-42X offers a differentiated approach by targeting two key physiological pathways (intermittent hypoxia and hypercapnia) that underlie OSA, potentially benefiting a wider range of patients, including the 67% not classified as obese.

Risks

• The continued availability of financing for company operations.
• Incannex's ability to raise capital to fund continuing operations, complete capital raising transactions, and maintain or potentially further improve its capital structure.
• The potential impact of any infringement actions or other litigation brought against Incannex.
• The success of Incannex's development efforts, including its ability to progress drug candidates through clinical trials on the expected timelines.
• Competition from other providers and products in the therapeutic areas Incannex targets.
• The market for its drug candidates may not grow at the rates anticipated or at all.
• Incannex's compliance with the various evolving and complex laws and regulations applicable to its business and industry.
• Incannex's ability to protect its proprietary technology and intellectual property.
• The results of earlier clinical trials may not be representative or consistent with later clinical trials or final results.

Future Outlook

Incannex Healthcare Inc. is on track to deliver top-line results from the RePOSA Phase 2 clinical trial of IHL-42X in July 2025. The company aims to commercialize IHL-42X as a first-in-class, market-leading therapeutic solution for obstructive sleep apnoea, addressing a condition affecting hundreds of millions globally with no approved oral pharmacological treatment. The global Phase 2/3 clinical trial is expected to enroll more than 560 patients at sites worldwide.

Management Comments

• "Achieving database lock on schedule demonstrates our strong clinical capabilities and commitment to advancing a much-needed therapy for obstructive sleep apnoea." Joel Latham, President and CEO of Incannex.
• "IHL-42X represents a breakthrough opportunity to address a condition affecting hundreds of millions of people globally, with no approved oral pharmacological treatment available." Joel Latham, President and CEO of Incannex.
• "We are excited by what lies ahead." Joel Latham, President and CEO of Incannex.

Industry Context

Obstructive Sleep Apnoea (OSA) affects an estimated 1 billion people globally and approximately 30 million in the United States, yet it remains significantly underdiagnosed and undertreated. There is currently no approved oral pharmacological treatment for OSA, making IHL-42X a potential first-in-class therapy that could disrupt the treatment paradigm. The drug's mechanism, targeting intermittent hypoxia and hypercapnia, offers a differentiated approach compared to existing options like CPAP or weight loss therapies, potentially benefiting a wider range of patients, including non-obese individuals.

Comparison to Industry Standards

• The document highlights that there is "no approved oral pharmacological treatment available" for Obstructive Sleep Apnoea (OSA), positioning IHL-42X as a potential "first-in-class" drug.
• It contrasts IHL-42X with Continuous Positive Airway Pressure (CPAP) devices, noting that IHL-42X is designed for patients "unable or unwilling to use CPAP" and offers a "patient-friendly alternative."
• Unlike weight loss therapies, IHL-42X is "uniquely engineered to target two key physiological pathways, intermittent hypoxia (IH) and hypercapnia, that underlie the pathology of OSA," which may benefit a wider range of patients, including the 67% of individuals with OSA who are not classified as obese.
• The prior Australian Phase 2 clinical trial showed IHL-42X reduced the Apnea-Hypopnea Index (AHI) by an average of 51% relative to baseline, which is a significant reduction for OSA treatment.

Legal Proceedings

• The company lists "the impact of any infringement actions or other litigation brought against Incannex" as a general risk, but no specific current legal proceedings are detailed.

Stakeholder Impact

• Shareholders: Positive impact due to on-schedule progress of a key clinical trial, potential for future value creation if IHL-42X is successful in a large, underserved market.
• Patients with OSA: Potential for a new, patient-friendly oral treatment option for a chronic condition that currently lacks approved pharmacological solutions, especially for those unable or unwilling to use CPAP.
• Employees: Positive outlook on the company's progress and commitment to advancing its drug pipeline.

Next Steps

• Final statistical analysis of the RePOSA Phase 2 clinical trial data.
• Delivery of top-line results from the U.S. Phase 2 portion of the RePOSA trial in July 2025.
• Continued advancement of the global Phase 2/3 clinical trial for IHL-42X, expected to enroll over 560 patients worldwide.

Key Dates

Recommendation

Keywords

Incannex Healthcare, IXHL, IHL-42X, Obstructive Sleep Apnoea, OSA, RePOSA, Phase 2 trial, clinical trial, database lock, biopharmaceutical, drug development, sleep apnea treatment, dronabinol, acetazolamide, AHI, CPAP alternative, clinical-stage